Introduction The field of cancer therapy has undergone a major transformation in less than a
decade due to the introduction of checkpoint inhibitors, the advent of next generation …

Efanesoctocog alfa (Altuviiio, TM Sanofi-SOBI) is a B domain-deleted single-chain Factor VIII
(FVIII) connected to D'D3 domain of von Willebrand Factor (vWF). Its ingenious design …

Peptide drugs play an important part in medicine owing to their many therapeutic
applications. Of the 80 peptide drugs approved for use in humans, at least five are now off …

Introduction Clinical trials of personalized cancer vaccines have shown that on-demand
therapies that are manufactured for each patient, result in activated T cell responses against …

In silico immunogenicity risk assessment has been an important step in the development
path for many biologic therapeutics, including monoclonal antibodies. Even if the source of a …

The identification and removal of host cell proteins (HCPs) from biologic products is a critical
step in drug development. Despite recent improvements to purification processes, biologics …

Pathogens escape host defenses by T-cell epitope mutation or deletion (immune escape)
and by simulating the appearance of human T cell epitopes (immune camouflage). We …

Biologics developers are moving beyond antibodies for delivery of a wide range of
therapeutic interventions. These non-antibody modalities are often based on 'natural'protein …

Infantile-onset Pompe disease (IOPD) is a glycogen storage disease caused by a deficiency
of acid alpha-glucosidase (GAA). Treatment with recombinant human GAA (rhGAA …

Alzheimer's disease (AD) is a neuropathology characterized by progressive cognitive
impairment and dementia. The disease is attributed to senile plaques, which are aggregates …